Skip to main content

MoneyWorks4Me

Claris Lifesciences gets 18 observations from USFDA for Ahmedabad plant: Report

09 Aug 2017 Evaluate

Claris Lifesciences has reportedly received 18 observations from US Food and Drug Administration (USFDA) for its Ahmedabad plant. This was inspected between July 27 and August 4, 2017. The Ahmedabad site is an Ex-Claris injectable site as the company sold its injectable business to Baxter for $625 million.

Claris Lifesciences is engaged in manufacturing of drugs and pharmaceutical products. The Company manufactures and markets products across multiple delivery systems, markets and therapeutic segments, including anesthesia and analgesics, blood products, anti-invective's, critical care, and nephrology.

Peers
Company Name CMP
Redington 359.55
Adani Enterprises 2733.00
Amrapali Industries 33.62
Maxgrow India 182.35
Rashi Peripheral 696.70
View more..